Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etranacogene Dezaparvovec→

Etranacogene Dezaparvovec Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2156583-26-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Adeno-associated virus serotype 5 (AAV5) gene therapy delivering the factor IX Padua variant (FIX-Padua)
Mechanism of action
AAV5 vector delivers a functional F9 gene encoding the Padua variant of human coagulation factor IX to hepatocytes, enabling endogenous production of factor IX with increased specific activity and supporting haemostasis.
Indications / reported uses
  • Treatment of adults with haemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis, have a history of life-threatening haemorrhage, or have repeated serious spontaneous bleeding episodes, subject to product-specific criteria

Sources: US DailyMed — HEMGENIX (etranacogene dezaparvovec) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etranacogene Dezaparvovec Environmental Risk Assessment (ERA) (the Etranacogene Dezaparvovec ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.